Skip to main content
Clinical Trials/JPRN-jRCT2013210076
JPRN-jRCT2013210076
Recruiting
Phase 2

Treatment of lumbar canal stenosis with a combination of ultra-purified, allogenic, bone marrow-derived, mesenchymal stem cells (REC) and in situ-forming gel: a multicentre, prospective, double blind, randomised, controlled trial

Sudo Hideki0 sites45 target enrollmentMarch 18, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Sudo Hideki
Enrollment
45
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Sudo Hideki

Eligibility Criteria

Inclusion Criteria

  • 1\.Candidate for laminoplasty following lumbar discectomy for combined lumbar spinal canal stenosis (LSCS).
  • 2\. Radiographic findings corroborating symptoms of combined LSCS.
  • 3\. Condition unresponsive to six consecutive weeks of therapy or experiencing acute/uncontrolled leg pain, defined as a score \>80 on the 100\-mm visual analogue scale (VAS), in which higher scores represent worse pain.
  • 4\. Single\-level combined LSCS.
  • 5\. Persistent and predominant leg pain (score \>40 on the 100\-mm VAS)
  • 6\. Age between 20 and 75 years (inclusive).
  • 7\. Willingness to provide written informed consent, fill in all necessary questionnaires, and return for follow\-up.

Exclusion Criteria

  • 1\. Previous surgery involving a lumbar level.
  • 2\. Prior or planned spinal fusion involving a lumbar level.
  • 3\. Local kyphosis involving the affected disc level, evident on plain radiography of the lumbar spine in the flexion, neutral or extension position.
  • 4\. Intradiscal air pattern at the affected level.
  • 5\. Spondylolisthesis or retrolisthesis above grade 1 at the affected level.
  • 6\. IVD (height obtained by averaging the anterior and posterior heights of the IVD to be operated in the lumbar X\-ray image in the neutral position) less than or equal to an average half of the adjacent caudal disc height.
  • 7\. History of treatment with condoliase.
  • 8\. Severe hypersensitivity to serum albumin or antibiotics.
  • 9\. Acute local or systemic infection.
  • 10\. Active malignancy or other similar comorbidities.

Outcomes

Primary Outcomes

Not specified

Similar Trials